|
AU2016222497A1
|
|
Method of regulating glucose metabolism, and reagents related thereto
|
|
AU2014271353A1
|
|
Method of regulating glucose metabolism, and reagents related thereto
|
|
AU2012202550A1
|
|
Method of regulating glucose metabolism, and reagents related thereto
|
|
AU2007202745A1
|
|
Method of regulating glucose metabolism, and reagents related thereto
|
|
US2002123461A1
|
|
Enhancement of GLP-2 activity
|
|
AU7952001A
|
|
Ampk-related serine/threonine kinase, designated snark
|
|
CA2417802A1
|
|
Ampk-related serine/threonine kinase, designated snark
|
|
AU4675901A
|
|
Glp-2 receptor gene promoter and uses thereof
|
|
CA2340783A1
|
|
Ampk-related serine/threonine kinase, designated snark
|
|
AU2020501A
|
|
Chemotherapy treatment
|
|
WO9852600A1
|
|
Methods of enhancing functioning of the upper gastrointestinal tract
|
|
AU7421598A
|
|
Methods of enhancing functioning of the large intestine
|
|
CA2236519A1
|
|
Methods of enhancing functioning of the large intestine
|
|
US6051557A
|
|
Methods of enhancing functioning of the upper gastrointestinal tract
|
|
EP0981611A1
|
|
Polynucleotides encoding proexendin, and methods and uses thereof
|
|
GB9715481D0
|
|
Methods of enhancing functioning of the upper gastrointestinal tract
|
|
EP2009024A1
|
|
Glucagon-like peptide-2 analogs
|
|
US5846937A
|
|
Method of using exendin and GLP-1 to affect the central nervous system
|
|
GB9702582D0
|
|
Polynucleotides
|
|
US5952301A
|
|
Compositions and methods for enhancing intestinal function
|
